Evidence map›Paper›PMID 36428763›Full record

ArticleCancers2022

Melanoma of the Upper Limb and Shoulder: A Surveillance, Epidemiology, and End Results Analysis of Epidemiology and Survival 2000-2019.

Solange N Walz, Jérôme Martineau, Matteo Scampa, Daniel F Kalbermatten, Carlo M Oranges

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Interleukin-1β Gene (Current oncology (Toronto, Ont.) · 2026
    Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Solange N WalzDepartment of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, Geneva University, 1205 Geneva, Switzerland.ORCID 0000-0002-1023-8552
Jérôme MartineauDepartment of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, Geneva University, 1205 Geneva, Switzerland.ORCID 0000-0002-9385-6312
Matteo ScampaDepartment of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, Geneva University, 1205 Geneva, Switzerland.ORCID 0000-0003-0461-7596
Daniel F KalbermattenDepartment of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, Geneva University, 1205 Geneva, Switzerland.ORCID 0000-0002-6626-1233
Carlo M OrangesDepartment of Plastic, Reconstructive and Aesthetic Surgery, Geneva University Hospitals, Geneva University, 1205 Geneva, Switzerland.ORCID 0000-0003-1735-5329
University Hospital of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Melanoma is the most common life-threatening cancer among skin cancers. Almost all locations of the skin can be affected by melanoma, and the upper limbs are one of the most frequent locations. We aimed to study the epidemiology and survival outcomes of patients with melanoma localized in the upper extremities compared with other sites. (2) Methods: The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database is considered the most representative of the U.S. population; we extracted melanoma cases diagnosed between 2000 and 2019. Several characteristics, including demographical, pathological, and therapeutic, were recorded, and upper extremity melanomas and melanomas from other areas were compared. Overall survival was assessed, and the groups were compared. (3) Results: 69,436 patients had melanoma in the upper limbs and shoulders and 204,794 in other body parts. Overall, 35,267 patients with upper extremity melanoma were males, 34,169 were females, and the mean age was 60. For the rest of the body, there were 118,654 males and 86,140 females, with a mean age of 59. Surgery alone was the most commonly used treatment, while radiation therapy was the least used for all sites. Women appear to have better survival than men. Superficial spreading melanoma is the least lethal subtype, while nodular melanoma is the most dangerous. (4) Conclusion: Women under 50 are more at risk than men of the same age. The trend reverses after age 50 where men are at greater risk. In addition to gender and age, disease stage and major histologic subtypes influence survival.

Indexed as

dermato-oncologyepidemiologymalignantmelanomaSEERsurvival analysisupper limb and shoulder

Identifiers

PMID36428763
PMCPMC9688102
OpenAlexW4309738305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.